120 related articles for article (PubMed ID: 38621607)
21. Magnetic Resonance-Guided Stereotactic Body Radiation Therapy/Hypofractionated Radiation therapy for Metastatic and Primary Central and Ultracentral Lung Lesions.
Sandoval ML; Sim AJ; Bryant JM; Bhandari M; Wuthrick EJ; Perez BA; Dilling TJ; Redler G; Andreozzi J; Nardella L; Feygelman V; Latifi K; Rosenberg SA
JTO Clin Res Rep; 2023 May; 4(5):100488. PubMed ID: 37159821
[TBL] [Abstract][Full Text] [Related]
22. Long-term outcomes in patients with central and ultracentral non-small cell lung cancer treated with stereotactic body radiotherapy: single-institution experience.
Song X; Zhao L; Jiang N; Ding N; Zong D; Zhang N; Wang D; Wen J; He X; Kong C; Zhu X
Curr Probl Cancer; 2023 Jun; 47(3):100956. PubMed ID: 36966677
[TBL] [Abstract][Full Text] [Related]
23. Dose-Volume Predictors of Radiation Pneumonitis After Thoracic Hypofractionated Radiation Therapy.
Sasse A; Oh P; Saeed N; Yang DX; Hayman TJ; Knowlton CA; Peters GW; Campbell A; Laird J; Housri N; Park HS
Pract Radiat Oncol; 2024; 14(2):e97-e104. PubMed ID: 37984711
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic Radiotherapy for Ultra-Central Lung Oligometastases in Non-Small-Cell Lung Cancer.
Loi M; Franceschini D; Dominici L; Franzese C; Chiola I; Comito T; Marzo M; Reggiori G; Mancosu P; Tomatis S; Nuyttens J; Scorsetti M
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32260568
[TBL] [Abstract][Full Text] [Related]
25. Dose coverage impacts local control in ultra-central lung oligometastases treated with stereotactic radiotherapy.
Loi M; Franceschini D; Dominici L; Chiola I; Franzese C; D'Agostino GR; Navarria P; Marzo M; Paganini L; Comito T; Mancosu P; Tomatis S; Cozzi L; Alifano M; Scorsetti M
Strahlenther Onkol; 2021 May; 197(5):396-404. PubMed ID: 32970163
[TBL] [Abstract][Full Text] [Related]
26. Stereotactic Body Radiation Therapy (SBRT) for Oligorecurrent/Oligoprogressive Mediastinal and Hilar Lymph Node Metastasis: A Systematic Review.
Cozzi S; Alì E; Bardoscia L; Najafi M; Botti A; Blandino G; Giaccherini L; Ruggieri MP; Augugliaro M; Iori F; Sardaro A; Iotti C; Ciammella P
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681659
[TBL] [Abstract][Full Text] [Related]
27. Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation.
Repka MC; Aghdam N; Kataria SK; Campbell L; Suy S; Collins SP; Anderson E; Lischalk JW; Collins BT
Radiat Oncol; 2017 Oct; 12(1):162. PubMed ID: 29052514
[TBL] [Abstract][Full Text] [Related]
28. Stereotactic body radiotherapy for distant metastases to the head and neck.
Mutsaers A; Abugharib A; Poon I; Loblaw J; Bayley A; Zhang L; Chin L; Galapin M; Erler D; Sahgal A; Higgins K; Enepekides D; Eskander A; Karam I
Support Care Cancer; 2024 Mar; 32(4):230. PubMed ID: 38488881
[TBL] [Abstract][Full Text] [Related]
29. External validation of pulmonary radiotherapy toxicity models for ultracentral lung tumors.
Chen I; Wu AJ; Jackson A; Patel P; Sun L; Ng A; Iyer A; Apte A; Rimner A; Gomez D; Deasy JO; Thor M
Clin Transl Radiat Oncol; 2023 Jan; 38():57-61. PubMed ID: 36388248
[TBL] [Abstract][Full Text] [Related]
30. Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree.
Haseltine JM; Rimner A; Gelblum DY; Modh A; Rosenzweig KE; Jackson A; Yorke ED; Wu AJ
Pract Radiat Oncol; 2016; 6(2):e27-33. PubMed ID: 26577006
[TBL] [Abstract][Full Text] [Related]
31. Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study of 55 Patients.
Bhandari RP; Stanford JD; Packianathan S; Duggar WN; Kanakamedala MR; Zhang X; Giri SP; Kumar PP; Harrell LM; Mangana SH; Yang C; Vijayakumar S
Oncology; 2016; 91(4):194-204. PubMed ID: 27427761
[TBL] [Abstract][Full Text] [Related]
32. Pulmonary oligometastases treated by stereotactic body radiation therapy (SBRT): a single institution's experience.
Chai G; Yin Y; Zhou X; Hu Q; Lv B; Li Z; Shi M; Zhao L
Transl Lung Cancer Res; 2020 Aug; 9(4):1496-1506. PubMed ID: 32953521
[TBL] [Abstract][Full Text] [Related]
33. Single community-based institutional series of stereotactic body radiation therapy (SBRT) for treatment of liver metastases.
Anstadt EJ; Shumway R; Colasanto J; Grew D
J Gastrointest Oncol; 2019 Apr; 10(2):330-338. PubMed ID: 31032102
[TBL] [Abstract][Full Text] [Related]
34. Stereotactic body radiation therapy for benign spine tumors: is dose de-escalation appropriate?
Kalash R; Glaser SM; Flickinger JC; Burton S; Heron DE; Gerszten PC; Engh JA; Amankulor NM; Vargo JA
J Neurosurg Spine; 2018 Aug; 29(2):220-225. PubMed ID: 29799334
[TBL] [Abstract][Full Text] [Related]
35. Repeat stereotactic body radiation therapy (SBRT) for salvage of isolated local recurrence after definitive lung SBRT.
Kennedy WR; Gabani P; Nikitas J; Robinson CG; Bradley JD; Roach MC
Radiother Oncol; 2020 Jan; 142():230-235. PubMed ID: 31481272
[TBL] [Abstract][Full Text] [Related]
36. Stereotactic body radiation therapy for post-pulmonary lobectomy isolated lung metastasis of thoracic tumor: survival and side effects.
Xiong W; Xu Q; Xu Y; Sun C; Li N; Zhou L; Liu Y; Zhou X; Wang Y; Wang J; Bai S; Lu Y; Gong Y
BMC Cancer; 2014 Sep; 14():719. PubMed ID: 25260301
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors of local control and disease free survival in centrally located non-small cell lung cancer treated with stereotactic body radiation therapy.
Duijm M; van der Voort van Zyp NC; Granton PV; van de Vaart P; Mast ME; Oomen-de Hoop E; Hoogeman MS; Nuyttens JJ
Acta Oncol; 2020 Jul; 59(7):809-817. PubMed ID: 32286140
[No Abstract] [Full Text] [Related]
38. Low Incidence of Esophageal Toxicity After Lung Stereotactic Body Radiation Therapy: Are Current Esophageal Dose Constraints Too Conservative?
Yau V; Lindsay P; Le L; Lau A; Wong O; Glick D; Bezjak A; Cho BCJ; Hope A; Sun A; Giuliani M
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):574-580. PubMed ID: 29680259
[TBL] [Abstract][Full Text] [Related]
39. Feasibility study of stereotactic body radiotherapy for peripheral lung tumors with a maximum dose of 100 Gy in five fractions and a heterogeneous dose distribution in the planning target volume.
Takeda A; Oku Y; Sanuki N; Eriguchi T; Aoki Y; Enomoto T; Kaneko T; Nishimura S; Kunieda E
J Radiat Res; 2014 Sep; 55(5):988-95. PubMed ID: 24833770
[TBL] [Abstract][Full Text] [Related]
40. A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups.
Macchia G; Lazzari R; Colombo N; Laliscia C; Capelli G; D'Agostino GR; Deodato F; Maranzano E; Ippolito E; Ronchi S; Paiar F; Scorsetti M; Cilla S; Ingargiola R; Huscher A; Cerrotta AM; Fodor A; Vicenzi L; Russo D; Borghesi S; Perrucci E; Pignata S; Aristei C; Morganti AG; Scambia G; Valentini V; Jereczek-Fossa BA; Ferrandina G
Oncologist; 2020 Feb; 25(2):e311-e320. PubMed ID: 32043791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
